November 14, 2020
View Full PaperRivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
Structured PICO
Does rivaroxaban prevent death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve compared to warfarin?
P
Population
Patients with atrial fibrillation and a bioprosthetic mitral valve
I
Intervention
Rivaroxaban
C
Comparator
Warfarin
O
Outcome
Mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 monthscomposite
Rivaroxaban is noninferior to warfarin for the composite outcome of death, major cardiovascular events, or major bleeding in patients with atrial fibrillation and a bioprosthetic mitral valve.
Abstract
In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).